Morgan Stanley, Citigroup, JMP Securities, Oppenheimer will assist
By Devika Patel
Knoxville, Tenn., March 2 – Syndax Pharmaceuticals Inc. said it priced its $52.8 million initial public offering of stock with a $7.92 million greenshoe. The deal was announced Jan. 4.
The company will sell 4.4 million common shares at $12.00 per share.
Morgan Stanley & Co. LLC and Citigroup Global Markets Inc. are the bookrunners.
Settlement is expected on March 8.
Proceeds will be used for operations, clinical trials, working capital and general corporate purposes.
The biopharmaceutical company is based in Waltham, Mass. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “SNDX.”
| Issuer: | Syndax Pharmaceuticals Inc.
|
| Issue: | Common stock
|
| Amount: | $52.8 million
|
| Greenshoe: | $7.92 million, or 660,000 shares
|
| Shares: | 4.4 million
|
| Price: | $12.00
|
| Warrants: | No
|
| Bookrunners: | Morgan Stanley & Co. LLC and Citigroup Global Markets Inc.
|
| Co-managers: | JMP Securities and Oppenheimer & Co.
|
| Announcement date: | Jan. 4
|
| Pricing date: | March 2
|
| Settlement date: | March 8
|
| Stock exchange: | Nasdaq: SNDX
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
